What is Reapplix?
Reapplix is at the forefront of medical technology, focusing on personalized wound healing solutions, particularly for diabetic foot ulcers. Its proprietary 3C Patch System utilizes a small sample of the patient's blood to create a single patch, dramatically accelerating the healing process for challenging wounds. This evidence-based treatment option is designed to be cost-effective and is recognized by the International Working Group on the Diabetic Foot as a valuable adjunctive therapy for chronic wound patients, especially those with diabetes.
How much funding has Reapplix raised?
Reapplix has raised a total of $25.6M across 2 funding rounds:
Unspecified
$3M
Other Financing Round
$22.6M
Unspecified (2016): $3M with participation from Vækstfonden, Novo Seeds, and SEED Capital
Other Financing Round (2020): $22.6M, investors not publicly disclosed
Key Investors in Reapplix
Vækstfonden
Vækstfonden, now EIFO, is Denmark's national investment fund, providing crucial risk capital, loans, guarantees, and equity to Danish companies. It supports businesses across all stages, from startups to established exporters, with a focus on long-term growth and internationalization.
Novo Seeds
Novo Seeds is an early-stage investment arm associated with Novo Holdings, a prominent Danish investment company focused on life sciences and biotechnology, supporting innovative ventures in the healthcare sector.
SEED Capital
SEED Capital is a Danish venture capital firm specializing in early-stage technology and life science companies, providing strategic guidance and financial backing to foster innovation and growth.
What's next for Reapplix?
The substantial enterprise-level capital infusion positions Reapplix for significant scaling and further development of its innovative 3C Patch System. This strategic backing is expected to accelerate market penetration and expand the company's reach within the chronic wound care sector. Future growth will likely involve further clinical validation, broader commercialization efforts, and potentially exploring new applications for its personalized healing technology. The company's focus on a critical unmet medical need suggests a trajectory towards becoming a key player in advanced wound management.
See full Reapplix company page
